Microbiological Testing & Consulting, LLC - 720374 - 03/16/2026

Why It Matters

Non‑compliant contract testing labs jeopardize drug safety and expose manufacturers to regulatory sanctions, potentially disrupting supply chains and market access.

Key Takeaways

• FDA issued warning letter for CGMP violations at contract lab.
• Lab lacks documentation, media qualification, and training records.
• Quality unit failed oversight of OOS/OOL investigations.
• Data integrity lapses risk patient safety and regulatory action.
• Firm must submit corrective plan within 15 working days.

Pulse Analysis

The recent FDA warning letter to Microbiological Testing & Consulting, LLC underscores the heightened scrutiny contract laboratories face under the CGMP framework. As a GDUFA‑III participant, the lab is expected to meet rigorous standards for microbiological testing, documentation, and data integrity. The agency’s findings—ranging from missing equipment logs to inadequate media qualification—signal systemic gaps that could compromise the safety and efficacy of drug products tested by third‑party facilities. By demanding a detailed corrective‑action plan, the FDA aims to restore confidence in the laboratory’s ability to generate reliable results for pharmaceutical manufacturers.

Key deficiencies identified include the absence of scientifically sound test specifications, incomplete batch records, and a training program that fails to meet CGMP requirements. The quality‑control unit’s limited oversight of out‑of‑specification (OOS) and out‑of‑limit (OOL) investigations further erodes data reliability, raising red flags for both regulators and customers. Data‑integrity lapses, highlighted in the FDA’s guidance, pose a direct risk to patient safety and can trigger enforcement actions such as seizure, injunction, or loss of export certificates. For contract labs, these shortcomings not only threaten regulatory standing but also jeopardize commercial relationships and eligibility for federal contracts.

Industry players must view this warning as a cautionary example and proactively strengthen their quality systems. Implementing robust documentation practices, qualifying all microbiological media, and establishing a comprehensive OOS/OOL investigation protocol are essential first steps. Additionally, investing in continuous CGMP training and employing independent consultants to audit data‑integrity controls can accelerate compliance. Timely, transparent remediation not only mitigates enforcement risk but also reinforces the lab’s credibility, ensuring uninterrupted service to drug manufacturers and safeguarding the broader pharmaceutical supply chain.